Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NANP | Q8TBE9 | 3/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | NEU1 | Q99519 | 2/20 | 0.37 |
| ▸ | MAG | P20916 | 2/20 | 0.36 |
| ▸ | SELL | P14151 | 1/20 | 0.36 |
| ▸ | SELP | P16109 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27909377 | 1.00 | NANP (0.65) | NANPL3MBTL1NEU1MAGSELL | |
| SCHEMBL29632786 | 0.91 | NANP (0.67) | NANPL3MBTL1NEU1MAGSELL | |
| SCHEMBL20190565 | 0.91 | NANP (0.67) | NANPL3MBTL1NEU1MAGSELL | |
| SCHEMBL420656 | 0.91 | NANP (0.67) | NANPL3MBTL1NEU1MAGSELL | |
| SCHEMBL13190787 | 0.91 | NANP (0.67) | NANPL3MBTL1NEU1MAGSELL | |
| SCHEMBL29390472 | 0.91 | NANP (0.67) | NANPL3MBTL1NEU1MAGSELL | |
| SCHEMBL20968002 | 0.90 | NANP (0.61) | NANPL3MBTL1NEU1MAGSELL | |
| SCHEMBL14902803 | 0.90 | NANP (0.61) | NANPL3MBTL1NEU1MAGSELL | |
| SCHEMBL8661220 | 0.90 | NANP (0.52) | NANPL3MBTL1MAG | |
| SCHEMBL29569888 | 0.90 | NANP (0.52) | NANPL3MBTL1MAG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0524143-B1 | Process of preparation of activated sialic acids | CIBA GEIGY AG (CH) | 1997-12-10 | — | — | EP | claimed |
| US-5334514-A | Reacting sialic acid with cytidine 5*-triphosphate in presence of cell extract of microorganism having cytidine 5*-monophospho-N-acetylneuraminic acid synthetase activity | CIBA VISION CORPORATION | 1994-08-02 | — | — | US | claimed |
| EP-0524143-A1 | Process of preparation of activated sialic acids | CIBA-GEIGY AG (CH) | 1993-01-20 | — | — | EP | claimed |
| US-12582612-B2 | Pharmaceutical composition of Siglec-binding agents | CYTODIGM, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260055147-A1 | RECOMBINANT PROTEIN AND PREPARATION PROCESS THEREOF, PROTEIN ADJUVANT FOR VACCINE COMPRISING RECOMBINANT PROTEIN, AND USE OF RECOMBINANT PROTEIN FOR PREVENTING RESPIRATORY DISEASE | UNIV NAT TSING HUA (TW) | 2026-02-26 | — | — | US | disclosed |
| EP-4674984-A1 | COMPOSITIONS | CPTx GmbH (DE) | 2026-01-07 | — | — | EP | disclosed |
| EP-3962491-B1 | INTRACELLULAR DELIVERY OF ANTI-KRAS ANTIBODIES FORMULATED INTO NANOCAPSULES | UNIV SANTIAGO COMPOSTELA (ES) | 2025-08-06 | — | — | EP | disclosed |
| US-20240358653-A1 | NOVEL PARTICLE COMPOSITION COMPRISING SIALIC ACID BINDING LIGAND | CYTODIGM, INC. | 2024-10-31 | — | — | US | disclosed |
| US-20240189797-A1 | SEPARATION MEDIA AND PURIFICATION METHODS FOR CARBOHYDRATE BINDING DOMAIN CONTAINING MOLECULES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-13 | — | — | US | disclosed |
| US-20240190913-A1 | SEPARATION MEDIA AND PURIFICATION METHODS FOR CARBOHYDRATE CONTAINING MOLECULES USING THE SAME | DONALDSON COMPANY, INC. | 2024-06-13 | — | — | US | disclosed |
| US-20240190912-A1 | SEPARATION MEDIA AND PURIFICATION METHODS FOR CARBOHYDRATE CONTAINING MOLECULES USING THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-13 | — | — | US | disclosed |
| WO-2022261207-A1 | NOVEL PARTICLE COMPOSITION COMPRISING SIALIC ACID BINDING LIGAND | CYTODIGM, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| US-20220177603-A1 | INTRACELLULAR DELIVERY OF ANTI-KRAS ANTIBODIES FORMULATED INTO NANOCAPSULES | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2022-06-09 | — | — | US | disclosed |
| US-20220142935-A1 | PHARMACEUTICAL COMPOSITION OF SIGLEC-BINDING AGENTS | CYTODIGM, INC. | 2022-05-12 | — | — | US | disclosed |
| WO-2022076435-A1 | PHARMACEUTICAL COMPOSITION OF SIGLEC-BINDING AGENTS | PHOSPHOREX, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| EP-3962491-A1 | INTRACELLULAR DELIVERY OF ANTI-KRAS ANTIBODIES FORMULATED INTO NANOCAPSULES | Universidade De Santiago De Compostela (ES) | 2022-03-09 | — | — | EP | disclosed |
| EP-0704536-B1 | Method for the isolation and purification of nucleotid-activated sugars from biological sources | HOECHST AG (DE) | 1998-11-18 | — | — | EP | disclosed |
| EP-0524143-B1 | Process of preparation of activated sialic acids | CIBA GEIGY AG (CH) | 1997-12-10 | — | — | EP | disclosed |
| EP-0704536-A1 | Method for the isolation and purification of nucleotid-activated sugars from biological sources | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-04-03 | — | — | EP | disclosed |
| US-5334514-A | Reacting sialic acid with cytidine 5*-triphosphate in presence of cell extract of microorganism having cytidine 5*-monophospho-N-acetylneuraminic acid synthetase activity | CIBA VISION CORPORATION | 1994-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240189797-A1 | SEPARATION MEDIA AND PURIFICATION METHODS FOR CARBOHYDRATE BINDING DOMAIN CONTAINING MOLECULES | CACYBP, MGAM, MASP2 | NANP 1105/4885L3MBTL1 2639/4885NEU1 749/4885 |
| US-20240190913-A1 | SEPARATION MEDIA AND PURIFICATION METHODS FOR CARBOHYDRATE CONTAINING MOLECULES USING THE SAME | MGAM, MASP2, MGAM2 | NANP 282/4885L3MBTL1 4034/4885NEU1 209/4885 |
| US-20260055147-A1 | RECOMBINANT PROTEIN AND PREPARATION PROCESS THEREOF, PROTEIN ADJUVANT FOR VACCINE COMPRISING RECOMBINANT PROTEIN, AND USE OF RECOMBINANT PROTEIN FOR PREVENTING RESPIRATORY DISEASE | LTA, TIMCC, CMBL | NANP 3442/4885L3MBTL1 388/4885NEU1 2192/4885 |
| US-20220142935-A1 | PHARMACEUTICAL COMPOSITION OF SIGLEC-BINDING AGENTS | SIGLEC7, SIGLEC9, SELPLG | NANP 1206/4885L3MBTL1 4868/4885NEU1 26/4885 |
| US-20240190912-A1 | SEPARATION MEDIA AND PURIFICATION METHODS FOR CARBOHYDRATE CONTAINING MOLECULES USING THE SAME | MGAM, CA14, MASP2 | NANP 357/4885L3MBTL1 3910/4885NEU1 161/4885 |
| US-20240358653-A1 | NOVEL PARTICLE COMPOSITION COMPRISING SIALIC ACID BINDING LIGAND | SIGLEC9, SIGLEC7, SELPLG | NANP 65/4885L3MBTL1 3860/4885NEU1 5/4885 |
| US-20220177603-A1 | INTRACELLULAR DELIVERY OF ANTI-KRAS ANTIBODIES FORMULATED INTO NANOCAPSULES | KRAS, NRAS, TP53 | NANP 3811/4885L3MBTL1 1735/4885NEU1 3414/4885 |
| US-12582612-B2 | Pharmaceutical composition of Siglec-binding agents | SIGLEC7, SIGLEC9, CD2 | NANP 221/4885L3MBTL1 4101/4885NEU1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.